X4 Pharmaceuticals (XFOR) Accounts Payables (2017 - 2025)

X4 Pharmaceuticals' Accounts Payables history runs 9 years deep, the most recent figure standing at $5.7 million for Q4 2025.

• Quarterly Accounts Payables fell 33.93% year-over-year to $5.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.7 million (down 33.93% YoY) and the FY2025 annual result came in at $5.7 million, down 33.93% from the prior year.
• Accounts Payables was $5.7 million for Q4 2025 at X4 Pharmaceuticals, up from $5.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.1 million in Q1 2025 and bottomed at $2.4 million in Q3 2021.
• A 5-year average of $6.2 million and a median of $5.8 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables jumped 147.68% — and 2025, when it sank 41.09%.
• X4 Pharmaceuticals' Accounts Payables stood at $4.3 million in 2021, then surged by 81.58% to $7.8 million in 2022, then gained by 15.04% to $8.9 million in 2023, then retreated by 3.64% to $8.6 million in 2024, then plunged by 33.93% to $5.7 million in 2025.
• Business Quant data shows XFOR's Accounts Payables at $5.7 million in Q4 2025, $5.1 million in Q3 2025, and $7.7 million in Q2 2025.